435
Participants
Start Date
February 5, 2018
Primary Completion Date
December 28, 2018
Study Completion Date
January 7, 2020
Bimekizumab
Bimekizumab will be provided at pre-specified time intervals.
Placebo
Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Ps0013 968, New York
Ps0013 965, New York
Ps0013 947, Buffalo
Ps0013 963, Rochester
Ps0013 966, Sandy Springs
Ps0013 928, Fort Myers
Ps0013 962, Owensboro
Ps0013 954, Skokie
Ps0013 944, New Orleans
Ps0013 914, San Antonio
Ps0013 933, Murray
Ps0013 967, Santa Monica
Ps0013 919, San Diego
Ps0013 955, San Diego
Ps0013 929, Portland
Ps0013 940, Beverly
Ps0013 901, Portsmouth
Ps0013 956, Verona
Ps0013 949, Cleveland
Ps0013 937, Johnston
Ps0013 003, Carlton
Ps0013 008, East Melbourne
Ps0013 006, Kogarah
Ps0013 658, Ajax
Ps0013 672, Edmonton
Ps0013 671, Hamilton
Ps0013 675, Markham
Ps0013 663, Mississauga
Ps0013 660, Montreal
Ps0013 668, North Bay
Ps0013 667, Ottawa
Ps0013 665, Québec
Ps0013 676, Surrey
Ps0013 657, Waterloo
Ps0013 202, Hamburg
Ps0013 220, Hamburg
Ps0013 219, Münster
Ps0013 200, Schwerin
Ps0013 204, Witten
Ps0013 261, Budapest
Ps0013 262, Miskolc
Ps0013 253, Orosháza
Ps0013 260, Szeged
Ps0013 250, Szolnok
Ps0013 258, Veszprém
Ps0013 355, Bialystok
Ps0013 361, Bialystok
Ps0013 369, Bialystok
Ps0013 352, Gdansk
Ps0013 358, Katowice
Ps0013 359, Katowice
Ps0013 366, Katowice
Ps0013 357, Kielce
Ps0013 363, Krakow
Ps0013 360, Lodz
Ps0013 356, Lublin
Ps0013 374, Poznan
Ps0013 353, Szczecin
Ps0013 350, Warsaw
Ps0013 351, Warsaw
Ps0013 354, Warsaw
Ps0013 365, Wroclaw
Ps0013 368, Wroclaw
Ps0013 370, Wroclaw
Ps0013 400, Moscow
Ps0013 402, Moscow
Ps0013 403, Moscow
Ps0013 404, Saint Petersburg
Ps0013 405, Saint Petersburg
Ps0013 401, Saratov
Ps0013 406, Yaroslavl
Ps0013 701, Busan
Ps0013 705, Seongnam-si
Ps0013 703, Seoul
Ps0013 550, Manchester
Ps0013 554, Reading
Ps0013 555, Salford
UCB Biopharma SRL
INDUSTRY